G vs NVDA

Genpact presents a classic value-trap profile, characterized by a stable Piotroski F-Score of 4/9 and a current price ($34.32) trading very close to its Graham Number ($32.47). While the company maintains a strong ROE of 22.37% and a very attractive forward P/E of 7.73, these fundamentals are offset by a disastrous technical trend (0/100) and bearish insider activity. The core business faces significant existential risks from generative AI, which the 10-K explicitly notes could replace existing services and reduce demand. Consequently, the deep valuation discount is likely a reflection of the market pricing in structural industry disruption.

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.